BDX Becton Dickinson

Q1 2025 10-Q

Filed: May 1, 2025Period ending Mar 31, 2025

Health Care

Surgical & Medical Instruments & ApparatusSEC EDGAR

Becton Dickinson (BDX) 10-Q quarterly report for Q1 2025, filed with SEC EDGAR on May 1, 2025 for the fiscal period ending Mar 31, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.

AI Filing Analysis
Q1 2025 10-Q

Risk Factors

• New risk: U.S. tariffs and countermeasures may reduce global trade, impact supply chain costs, particularly affecting operations in China
• Updated legal risk: Increased global enforcement of anti-corruption laws elevates risk of fines linked to international operations under Foreign Corrupt Practices Act

+3 more insights

Quarterly Financial Summary
XBRL

Revenue

$5.2B

Net Income

$303M

Operating Margin

8.8%

Net Margin

5.9%

ROE

1.2%

Total Assets

$54.8B

Source: XBRL data from Becton Dickinson Q1 2025 10-Q filing on SEC EDGAR. All figures in USD.

Other Becton Dickinson Quarterly Reports

Q4 2025 10-Q

Q2 2025 10-Q

Get deeper insights on Becton Dickinson

Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.